FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor
The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed sepsis.
The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed sepsis.
What's Your Reaction?
